Patients with dMMR, particularly those with isolated MSH2 or MSH6 loss, may benefit from genetic counseling and germline testing to identify potential Lynch syndrome cases, which could impact both patient management and familial cancer risk assessment. Here, MSH2 is linked to cancer.